A few days ago, GDBL Medical Equipment Technology Group released a layout plan for the entire industry chain of hemodialysis in Suzhou. This is the first time that GDBL has released a hemodialysis industry-wide strategy after it announced the acquisition of Suzhou JK Medical Technology Co., Ltd.
Suzhou JK's main products are hemodialysis membranes and hemodialyzers. Among them, hemodialysis membranes are the key material for dialyzers. Suzhou JK has the latest technology of hemodialysis machines and has an annual output of 4 million sets. Previously, they were mainly sold abroad. It is worth mentioning that Suzhou JK is the first manufacturer in China that fully masters the PES film drawing process, and its technology is leading domestically.
"The acquisition of Suzhou JK can bring great synergies to GDBL. GDBL has a global sales network and channels. There is no pressure to digest the annual output of 4 million sets of hemodialysis devices. The biggest problem now is that the production capacity cannot keep up. In the future, the scale of Suzhou JK hemodialyzer will be expanded by 5 times to an annual output of 20 million sets.” Recently, GDBL chairman Yan Jinyuan said in an interview with reporters.
Will be expanded by 5 times in the future
GDBL successfully took Suzhou JK into the arms of the hemodialysis industry. On September 18 this year, GDBL disclosed that it plans to acquire a 51% stake in Suzhou JK for RMB 118 million.
The acquisition of Suzhou JK is an important move of GDBL in the overall industry layout of hemodialysis. Suzhou JK has China's most advanced hemodialysis machine and hemodialysis membrane production line. This hemodialysis field is the most domestically produced product that can replace imported products. It will effectively fill the technical gap of GDBL in the upstream high barrier dialysis high-value consumables field.
The dialyzer is one of the necessary consumables for hemodialysis patients with end-stage renal disease. However, the hollow fiber membrane used in the production of the dialyzer is thinner than the hair, which requires extremely high equipment and technology. In China, Suzhou JK is the head manufacturer of hollow fiber membranes. Its main products are hemodialysis membranes and hemodialysis machines. For many years, the hollow fiber membranes produced by Suzhou JK have gained excellent reputation overseas.
"At present, we are still investing. The hemodialysis market is greatly affected by medical insurance policies, regional radiation, bidding, etc. After the acquisition of Suzhou JK, we have made up the most important link in the upstream and have the most advanced production technology and products. In recent years, expansion of production capacity and expansion of sales network are the main tasks. We are also advancing the layout of the downstream service field simultaneously. For example, production capacity guarantee is expected to double our sales next year, and we are still in the stage of vigorously launching. After the production capacity is expanded, the marginal cost diminishing effect will bring the harvest period." Yan Jinyuan told reporters.
Accelerate domestic replacement of hemodialysis consumables
"Globally, the current blood purification market is mainly concentrated in developed countries such as the United States and Japan, accounting for more than 70%. China's blood purification market started late and is small in scale. However, with the continuous increase in the number of kidney patients and the reimbursement of dialysis costs, medical insurance As the ratio continues to increase, the growth rate of China's blood purification market will accelerate rapidly." Yan Jinyuan explained to reporters.
GDBL benchmarked against Fresenius, the global hemodialysis industry giant, has been deeply involved in the field of hemodialysis for nearly 10 years.
Judging from the revenue in recent years, GDBL's deep cultivation in the field of hemodialysis has achieved initial results, and hemodialysis products have contributed to the main operating income. "We have been investing in high-barrier products such as hemodialyzers and hemodialysis in recent years, because the industry has high barriers and requires years of precipitation, which may not be immediately visible." Yan Jinyuan said.
At present, in the hemodialysis industry chain, only low-end hemodialysis equipment and consumables such as hemodialysis pipelines and hemodialysis powder are domestically produced in the upstream, and high-end hemodialysis equipment with high technical thresholds such as hemodialysis devices and hemodialysis machines are still imported Mainly, most of the upstream market is still firmly occupied by foreign companies. Hemodialysis drugs are mainly EPO (erythropoietin) and low molecular weight heparin. EPO has basically realized domestic substitution of imported, and the localization of heparin is accelerating.
In order to consolidate its position as the leading domestic brand, GDBL plans to invest another 800 million yuan into the hemodialysis market. "Mainly to enhance the competitive advantage of extracorporeal circulation pipelines, consolidate the moat of hemodialysis concentrate, build a professional and efficient marketing service network, accelerate the landing of adsorption and plasma treatment products, and build the world's most advanced comprehensive research and development center." Purpose, Yan Jinyuan told reporters.